Description of Collaborative Activity: |
Building on the momentum of the 2019 BMC Medicine Stigma Collection and the 2019 NIMH Global Mental Health Webinar, representatives from the National Institutes of Health (NIH) formed a Stigma Planning Workgroup to harness the momentum of the 2019 BMC Medicine Stigma Collection and the 2019 NIMH Global Mental Health Webinar and to coordinate and chart a course forward for research related to stigma. The overall goal was to provide leadership, vision, and support to stigma research funded by the NIH. As the NIH-focused workgroup started to meet and gain traction, other federal partners expressed interest in joining. For example, staff from the Centers for Disease Control and Prevention (CDC), Health Resources and Services and Administration (HRSA), Indian Health Services (IHS), Food and Drug Administration (FDA), and Substance Abuse and Mental Health Services Administration (SAMHSA) joined as well. Thus, moving forward this workgroup consists of Health and Human Services (HHS) partners aiming to promote cross-cutting stigma research and related activities and to enhance opportunities for knowledge transfer and collaborative learning in the field of stigma and discrimination research. To achieve this goal, the workgroup agrees to pursue several broad actions, including: (1) Clearly defining stigma and discrimination for the purpose of the workgroup; (2) Organizing a speaker’s series to understand current stigma research findings, and interests within each federal agency; (3) Identifying and defining current stigma and discrimination research successes and challenges within each agency; (4) Identifying shared and individual priorities for each agency and how future activities could address identified challenges; (5) See enclosed list of HHS partner interests; (6) Advancing stigma and discrimination research training to build knowledge and skills among stigma-focused researchers and among other researchers seeking to increase capacity to conduct high-quality stigma and discrimination research; (7) Advancing the broader dissemination of stigma-related research; (8) Aligning technical assistance efforts to support one another; and (9) Supporting cross-cutting stigma and discrimination research as a field. |
HHS Agency Collaborators on this Activity: |
CDC, FDA, HRSA, IHS, SAMHSA |
